Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Buys 10,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Altimmune Price Performance

NASDAQ ALT opened at $5.92 on Monday. The company’s 50 day simple moving average is $6.48 and its 200 day simple moving average is $7.12. Altimmune, Inc. has a 12 month low of $5.14 and a 12 month high of $11.16. The company has a market capitalization of $455.92 million, a P/E ratio of -3.82 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Stifel Nicolaus assumed coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bellevue Group AG increased its position in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Altimmune in the third quarter worth approximately $674,000. Barclays PLC increased its position in shares of Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after acquiring an additional 75,064 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Stifel Financial Corp increased its position in shares of Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.